- Home
- CSBR vs CGEN Comparison
CSBR vs CGEN Comparison
Compare CSBR & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSBR | CGEN |
|---|---|---|
| Founded | 1985 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.0M | 143.1M |
| IPO Year | 1986 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CSBR | CGEN |
|---|---|---|
| Price | $7.01 | $1.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 23.1K | ★ 397.7K |
| Earning Date | 12-15-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $58,424,000.00 | $6,903,000.00 |
| Revenue This Year | $4.84 | N/A |
| Revenue Next Year | $11.51 | $231.15 |
| P/E Ratio | $40.00 | ★ N/A |
| Revenue Growth | ★ 9.06 | N/A |
| 52 Week Low | $5.59 | $1.13 |
| 52 Week High | $11.99 | $2.66 |
Technical Indicators
Market Signals| Indicator | CSBR | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 43.67 |
| Support Level | $6.74 | $1.47 |
| Resistance Level | $7.39 | $1.55 |
| Average True Range (ATR) | 0.57 | 0.08 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 37.50 | 16.01 |
Price Performance
Historical ComparisonAbout CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.